Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Pongratz

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Deutsche Medizinische Wochenschrift (1946)|November 9, 2016
[Glucocorticoid therapy in rheumatoid arthritis - pro]Georg Pongratz
Current Pharmaceutical Design|May 23, 2012
Anti citrullinated protein antibodies and mechanism of action of common disease modifying drugs--insights in pathomechanisms of autoimmunityGeorg Pongratz, Martin Fleck
Nature Reviews. Rheumatology|November 14, 2012
Role of peripheral nerve fibres in acute and chronic inflammation in arthritisGeorg Pongratz, Rainer H Straub
Zeitschrift Fur Rheumatologie|July 24, 2023
[Role of the sympathetic nervous system in chronic inflammation]Georg Pongratz, Rainer H Straub
Arthritis Research & Therapy|March 20, 2015
The sympathetic nervous response in inflammationGeorg Pongratz, Rainer H Straub
Immunologic Research|January 24, 2008
B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?Georg Pongratz, Rainer H Straub
Brain, Behavior, and Immunity|July 21, 2009
The B cell, arthritis, and the sympathetic nervous systemGeorg Pongratz, Rainer H Straub
Neuroimmunomodulation|May 26, 2023
Chronic Effects of the Sympathetic Nervous System in Inflammatory ModelsGeorg Pongratz, Rainer H Straub
Current Opinion in Rheumatology|March 29, 2019
Joints for joints: cannabinoids in the treatment of rheumatoid arthritisTorsten Lowin, Matthias Schneider, Georg Pongratz
Journal of Inflammation (London, England)|May 10, 2016
The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targetsTorsten Lowin, Georg Pongratz, Rainer H Straub
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Deutsche Medizinische Wochenschrift (1946)|November 9, 2016
[Glucocorticoid therapy in rheumatoid arthritis - pro]Georg Pongratz
Current Pharmaceutical Design|May 23, 2012
Anti citrullinated protein antibodies and mechanism of action of common disease modifying drugs--insights in pathomechanisms of autoimmunityGeorg Pongratz, Martin Fleck
Nature Reviews. Rheumatology|November 14, 2012
Role of peripheral nerve fibres in acute and chronic inflammation in arthritisGeorg Pongratz, Rainer H Straub
Zeitschrift Fur Rheumatologie|July 24, 2023
[Role of the sympathetic nervous system in chronic inflammation]Georg Pongratz, Rainer H Straub
Arthritis Research & Therapy|March 20, 2015
The sympathetic nervous response in inflammationGeorg Pongratz, Rainer H Straub
Immunologic Research|January 24, 2008
B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?Georg Pongratz, Rainer H Straub
Brain, Behavior, and Immunity|July 21, 2009
The B cell, arthritis, and the sympathetic nervous systemGeorg Pongratz, Rainer H Straub
Neuroimmunomodulation|May 26, 2023
Chronic Effects of the Sympathetic Nervous System in Inflammatory ModelsGeorg Pongratz, Rainer H Straub
Current Opinion in Rheumatology|March 29, 2019
Joints for joints: cannabinoids in the treatment of rheumatoid arthritisTorsten Lowin, Matthias Schneider, Georg Pongratz
Journal of Inflammation (London, England)|May 10, 2016
The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targetsTorsten Lowin, Georg Pongratz, Rainer H Straub
Pageof 6